Abstract 14992: Should Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) be Discharged on Sacubitril/Valsartan or ACEi/ARB: A Decision Analysis Approach

Introduction: In the PARADIGM-HF study, sacubitril/valsartan demonstrated a 16% decrease in all-cause mortality and a 21% decrease in heart failure hospitalization. Cost and concern for a higher ri...